ASAN FOUNDATION

Korea launched the National Bio Big Data Initiative to establish a comprehensive bio big data platform for precision and personalized medicine, aiming to collect data from one million participants by 2032. The initiative integrates clinical, public health, and genomic data through voluntary participation, with data to be available for research from 2026.

Chang Gung Memorial Hospital, Linkou validated for Stage 7 of HIMSS INFRAM and Stage 6 of DIAM, focusing on cybersecurity, infrastructure maturity, and digital imaging. The hospital plans to invest in data analytics and medical imaging management, aiming for Stage 7 DIAM and adopting AI, big data, and FHIR standards for telemedicine interoperability.

The ATTENTION trial in Korea and Taiwan showed Vemlidy (tenofovir alafenamide) significantly reduced liver-related events in non-cirrhotic hepatitis B patients with normal ALT levels, emphasizing early treatment's importance to prevent HCC and reduce healthcare costs.

In a phase 1 study of PHI-101 for AML, 50% of evaluable patients achieved an overall complete response. PHI-101 targets FLT3 gene mutation in AML patients, presenting at ASH 2024. Pharos iBio plans to complete phase 1 and proceed with early commercialization.

PREC to review Ofev (nintedanib) for pulmonary fibrosis; Boehringer Ingelheim seeks reimbursement after 8 years; ICER threshold elasticity crucial for economic assessment; Ofev remains unreimbursed despite high costs and patient need.

TiumBio's phase 2 trial of TU2218, an oral dual inhibitor targeting TGFR1 and VEGFR2, begins with the first dose administered to an HNSCC patient. TU2218 aims to enhance the efficacy of immune checkpoint inhibitors by blocking TGF-ß and VEGF pathways. The trial, starting in South Korea and expanding to the U.S., will assess safety and efficacy in HNSCC, BTC, and CRC patients, following positive results in phase 1b with an 80% disease control rate.

TU2218, a dual inhibitor targeting TGFR1 and VEGFR2, has dosed its first head and neck squamous cell carcinoma patient in a Phase 2a trial, with plans to expand to biliary tract and colorectal cancer patients. The trial aims to improve immune checkpoint inhibitor efficacy by blocking TGF-ß and VEGF pathways.